https://scholars.lib.ntu.edu.tw/handle/123456789/458239
標題: | Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum | 作者: | Hsiao S.-M CHI-AN CHEN HO-HSIUNG LIN CHANG-YAO HSIEH LING-HUNG WEI |
公開日期: | 2009 | 卷: | 112 | 期: | 1 | 起(迄)頁: | 35-39 | 來源出版物: | Gynecologic Oncology | 摘要: | Objective: To evaluate the effectiveness and toxicity of distearoylphosphatidylcholine pegylated liposomal doxorubicin (DPLD) combined with carboplatin for the treatment of platinum-sensitive, paclitaxel-pretreated, recurrent, epithelial ovarian cancer. Methods: A phase II study of carboplatin/DPLD treatment for platinum-sensitive, paclitaxel-pretreated, recurrent, epithelial ovarian cancer was initiated in July 2002. As of March 2008, a total of 32 patients were enrolled. Results: Of the 32 patients, one achieved a complete response; 19 (59%) achieved a partial response. The overall objective response rate was 62% (95% confidence interval [CI], 45%-80%). The median progression-free survival and overall survival for all 32 patients was 9.1?months (95% CI, 6.4-10.4?months) and 27.9?months (95% CI, 13.9-38.6?months), respectively. Toxicity was tolerable. The most common grade 3 or 4 toxicities were anemia (n = 3) and nausea/vomiting (n = 3). Grade 3/4 leukopenia (n = 2), grade 3/4 thrombocytopenia (n = 2) and grade 4 hepatitis (n = 1) occurred in five patients. Conclusion: Carboplatin/DPLD appears to be an effective regimen with low toxicity for treatment of patients with platinum-sensitive, paclitaxel-pretreated, recurrent, epithelial ovarian cancer. ? 2008 Elsevier Inc. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/458239 | ISSN: | 0090-8258 | DOI: | 10.1016/j.ygyno.2008.09.033 | SDG/關鍵字: | carboplatin; cisplatin; cyclophosphamide; doxorubicin; gemcitabine; paclitaxel; platinum; topotecan; adult; aged; anemia; article; bloodstream infection; cancer chemotherapy; clinical trial; controlled study; diarrhea; disease free survival; drug efficacy; drug tolerability; female; hand foot syndrome; hepatitis; human; leukopenia; liver toxicity; major clinical study; multiple cycle treatment; nausea and vomiting; nephrotoxicity; neurotoxicity; ovary cancer; overall survival; phase 2 clinical trial; priority journal; stomatitis; thrombocytopenia; treatment response; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。